Biomedical expands manufacturing footprint through investment in new

Biomedical, a subsidiary of dsm-firmenich, is excited to announce that it has made a significant investment in a new facility, supporting its business portfolio growth.

Located at 400 Devon Park Drive in Pennsylvania, this expansion is driven by Biomedical’s strong growth in recent years and focused Specialized Biomaterials Manufacturing (SBM) strategy, offering MedTech Companies proven solutions to outsource their natural materials and polymeric based technologies by leveraging the company’s manufacturing and processing expertise.

“With this infrastructure expansion initiative, we are proud to showcase our commitment to growth alongside our partners,” says Gersen Gabriel, Vice President of Global Operations at Biomedical. “Building capacity will also allow our team to display our technical and processing proficiencies, giving them new grounds to continue our innovation efforts.”

Eric Shelton, Vice President of Global Commercial at Biomedical added, “This is a compliment to the Biomedical team, whose passion for bringing progress to life fuels our continued commitment to our partners. By leveraging our unrivaled expertise in biomaterial science as well as our processing know-how, we look forward to enabling our customers to grow within the medical device and pharma space.”

It is well-known that Biomedical is a leading biomaterial solutions provider for the medical industry. The company’s 30+ years of experience working with the world’s leading medical device and pharmaceutical companies ensures that its solutions meet the highest medical grade quality and consistency requirements globally. This commitment remains unchanged through Biomedical’s newest infrastructure expansion initiative, ultimately enabling it to bring progress to life for millions of patients worldwide through its company-wide vision of solving our world’s healthcare needs through sustainable science.

Located at 400 Devon Park Drive in Pennsylvania, this expansion is driven by Biomedical’s strong growth in recent years and focused Specialized Biomaterials Manufacturing (SBM) strategy.